Nutra Pharma Corporation OTCBB: NPHC   Overview Nutra Pharma Corp. (OTCBB: NPHC) Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. Mission Statement Nutra Pharma is dedicated to the success of its patients, customers, investors and business partners through its development and acquisition of innovative pharmaceutical and life science solutions that will improve the lives of people throughout the world. Nutra Pharma Corp. 791 Park Of Commerce Blvd Suite 300 Boca Raton, FL 33487 http://www.nutrapharma.com Intellectual Property Nutra Pharma seeks patent and other intellectual property rights to protect and preserve our proprietary technology and our right to capitalize on the results of our research and development activities. We also rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to prove competitive advantages for our products in our markets and to develop new products. Nutra Pharma holds a license to certain intellectual property from Bio Therapeutics, which it intends to utilize in conjunction with Receptopharm's research and development of modified venom and peptides thereof in applications for the treatment of HIV and MS. Patents U.S. Patent No. 5,989,857, which was granted in November 1999 with 10 claims. U.S. Patent No. 6,670,148, which was granted in December 2003, with 9 claims. The patent further describes the method for preparing a bioactive peptide (protein) found in cobra venom, in a stable, inactivated form, by treating the peptide with ozone. Buccal Delivery System, on which a patent is pending. This application describes a throat spray that permits efficient delivery of the modified peptide drugs to the body through oral mucosa. Technology contained in one pending U.S. patent application for the further development of bioactive peptides in cobra venom for use in the treatment of HIV and MS. Technology contained in two pending U.S. patent applications for Immunokine Composition and Method, which describes a method for developing modified peptides from alpha-cobratoxin. Technology contained in two patents pending for the topical delivery of our proprietary wound healing treatment, which was developed in conjunction with Bio Therapeutics. One of these products is in the form of an ointment style skin protectant and the other a foaming aerosol. R&D Pipeline Nutra Pharma, through its subsidiary ReceptoPharm, has a pipeline of biopharmaceutical products under development. These research and development pipeline products consist of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis, HIV/AIDS, adrenomyeloneuropathy, herpes, rheumatoid arthritis and pain. Click here to view the full pipeline.   Cobroxin Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Advanced Oral Spray   The Cobroxin Advanced Oral Spray has a pleasant tasting orange flavor, sweetened naturally with xylitol, so that it is safe for diabetics. Each bottle provides up to 30 days worth of relief. Specifically formulated to relieve: Shoulder pain Cramps Neuralgia Lower back pain Migraines Neck aches     Advanced Topical Gel   The Cobroxin Advanced Topical Gel is formulated to aide skin penetration with no scent or dyes. It also is non sticky and non-staining. Relieves pain associated with: Repetitive Stress Arthritis Joint Pain For additional information about Cobroxin, visit www.Cobroxin.com. Management Team Rik Deitsch Chairman and Chief Executive Officer Nutra Pharma Corporation Rik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November 7, 2002. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic . Mr. Deitsch is an adjunct professor and teaches several courses for Florida Atlantic University's College of Business and Continuing Education Department.     Paul F. Reid, Ph.D. Chief Executive Officer ReceptoPharm, Inc. Paul F. Reid, Ph.D., is a Co-Founder and Chief Executive Officer of ReceptoPharm. Dr. Reid is equipped with a broad scientific background, encompassing 14+ years in clinical development and research, with a direct approach to moving products from preclinical into clinical phases. He has worked and negotiated with drug regulatory agencies in the US, Canada, EU, South America, South Africa, and China, enabling companies to move ahead, save millions on research and testing in clinical trials, and gain IND approvals. By leveraging his comprehensive understanding of regulatory requirements he can guide new projects through the correct protocols at a minimum budget, advancing products, positioning for licensing, and setting up manufacturing. The application of his knowledge of laboratory practices to select new technologies that enhance production, quality control, and product formats. Dr. Reid is a leading world expert in the therapeutic use of snake venom neurotoxins.     Neil Roth President Designer Diagnostics, Inc. Neil Roth joined Nutra Pharma Corporation in 2005 as President of Designer Diagnostics, Inc. He has over 30 years experience in the sales and marketing of consumer goods including pharmaceuticals and medical devices. His prior experience included senior management and top marketing positions of major multibillion-dollar companies, including: Revco, Eckerd Drugs and Thrifty Drugs. He has successfully increased sales in the companies that he has been associated with through his expertise and understanding of the creation of marketing plans into new and developing markets.     David Isserman Chief Marketing Officer Nutra Pharma Corporation David Isserman joined Nutra Pharma Corporation in 2010 as Chief Marketing Officer after serving the Company for several years as an outside consultant. Prior to Joining Nutra Pharma, Mr. Isserman served as President of Isserman Consulting, a boutique marketing communications consultancy that advised early-stage biotechnology, consumer products and technology companies, and was a co-founder of RareShare, a website developed to connect patients and healthcare providers affected by rare medical disorders.  Over the past several years, Mr. Isserman has served on several scientific and environmental non-profit boards and currently serves as a Trustee for the Academy of Science of St. Louis. Mr. Isserman received his Master of Business Administration (MBA) from Columbia Business School in New York.

PLEASE NOTE: OTCStockReporter and/or its affiliates are not registered as Investment Advisors in any jurisdiction whatsoever.

Release of Liability: Through use of OTCStockReporter email newsletters and website you agree to hold OTCStockReporter, its operators, owners, and employees harmless and completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. OTCStockReporter and/or its affiliates may from time to time have positions in the securities mentioned herein, may increase or decrease such positions without notice, and may profit from such transactions. OTCStockReporter encourages readers and investors to supplement the information in these reports with independent research and other professional advice.

Privacy Statement

Discover the Secrets to
"Investing in Stocks"

Free Trader EBook Library

Master Your Trading Mindtraps

Tips and Tricks For a Trader to Make the Market Work For You

When To Sell Stocks